about
Selective Estrogen Receptor Modulation by Larrea nitida on MCF-7 Cell Proliferation and Immature Rat Uterus.Diagnosis and treatment of sarcoma of the uterus. A review.Mullerian adenosarcoma of the uterus with sarcomatous overgrowth.Adverse drug event monitoring at the Food and Drug Administration.Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGGBreast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen.Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society.Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancerUterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report.A Case of Metastatic Low-Grade Endometrial Stromal Sarcoma Treated with Letrozole after Ovarian Ablation by Radiotherapy.Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomicsUterine leiomyosarcoma manifesting as a tricuspid valve mass.Long-term safety of aromatase inhibitors in the treatment of breast cancer.Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.Hormonal therapy in gynecological sarcomas.High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids.Selective estrogen receptor modulators (SERMS).
P2860
Q34039793-7663E143-1B8C-437A-83B2-9DD1BD02D205Q34336818-FFA026E6-DD67-47CF-AC78-9F4BC51949B8Q34611387-CB8BBE39-FF95-49EA-A5CD-F65C11ADE73CQ34740872-B53907CD-8146-4A8D-983D-0CCE1911C409Q35180929-C3EE93B7-96BA-4FFC-B931-CC06228BD300Q35194482-35D32554-B4CD-4D3F-8F10-FBC0C69BAB6EQ35213089-D08E910C-E77F-4F76-A187-A25F73D49831Q36169971-EB016983-1856-4B88-B254-FEA5DF861438Q36176079-B3C9A372-AB72-414A-BAFD-E90FF10644F1Q36187054-CD9B0C96-5D4C-4435-BEFA-3219AB6A7CEDQ36717159-A7B0E510-6D4B-495D-A4C7-522EAE2092FDQ36744460-9B6C45CD-14F9-402B-A690-975AB349BEFFQ36822883-1EEB0590-D13C-43DC-97CD-047D5115A9FBQ37392149-18681DE1-7E7A-48C7-8B14-C0643312EBB8Q37483932-1ED90ABA-E1E3-467C-B7E1-08948CD14311Q38030590-D9D6D243-9B6D-4786-9BDF-DCFCF3E31313Q38239833-BF97B7FB-D0AC-4864-B4B9-11E0F8A5857EQ38851505-AA958636-BDDA-483C-9ED0-D75FE198FE7DQ49258132-B65FFD72-277B-41CC-B58F-A970DB4DB1A2Q55042739-20BC4DF2-1F85-4B65-B7F3-280F11AE89DB
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Uterine sarcoma associated with tamoxifen use.
@en
Uterine sarcoma associated with tamoxifen use.
@nl
type
label
Uterine sarcoma associated with tamoxifen use.
@en
Uterine sarcoma associated with tamoxifen use.
@nl
prefLabel
Uterine sarcoma associated with tamoxifen use.
@en
Uterine sarcoma associated with tamoxifen use.
@nl
P2093
P1476
Uterine sarcoma associated with tamoxifen use.
@en
P2093
Diane K Wysowski
Julie Beitz
Susan Flamm Honig
P304
P356
10.1056/NEJM200206063462319
P407
P577
2002-06-01T00:00:00Z